Tscan Therapeutics is trading at $0.19, up 6.13%, with no clear company-specific announcement identified for the November 2 move.
- The company’s press-release page shows no newer release than its October 6 update.
- The October 28 Cellares collaboration is recent background, but available coverage does not connect it to the move.
- Major U.S. indexes were also higher, making the broader positive market tone plausible context, not a confirmed direct cause.